Research programme: spleen tyrosine kinase inhibitors - Pfizer/Rigel
Latest Information Update: 29 Mar 2012
At a glance
- Originator Rigel Pharmaceuticals
- Class Small molecules
- Mechanism of Action IgE receptor antagonists; Syk kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Allergic asthma; Chronic obstructive pulmonary disease; Precursor cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 06 May 2011 Discontinued - Preclinical for Acute lymphoblastic leukaemia in USA (unspecified route)
- 06 May 2011 Discontinued - Preclinical for Allergic asthma in USA (Inhalation)
- 06 May 2011 Discontinued - Preclinical for Chronic obstructive pulmonary disease in USA (Inhalation)